BNOX vs. VAXX, TRVN, CANF, EFTR, OGEN, VIRI, OBSV, HEPA, CYCN, and CVKD
Should you be buying Bionomics stock or one of its competitors? The main competitors of Bionomics include Vaxxinity (VAXX), Trevena (TRVN), Can-Fite BioPharma (CANF), eFFECTOR Therapeutics (EFTR), Oragenics (OGEN), Virios Therapeutics (VIRI), ObsEva (OBSV), Hepion Pharmaceuticals (HEPA), Cyclerion Therapeutics (CYCN), and Cadrenal Therapeutics (CVKD). These companies are all part of the "pharmaceutical preparations" industry.
Vaxxinity (NASDAQ:VAXX) and Bionomics (NASDAQ:BNOX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, community ranking, dividends, analyst recommendations, earnings, profitability and institutional ownership.
Bionomics has lower revenue, but higher earnings than Vaxxinity.
In the previous week, Vaxxinity and Vaxxinity both had 2 articles in the media. Vaxxinity's average media sentiment score of 1.58 beat Bionomics' score of 1.44 indicating that Bionomics is being referred to more favorably in the news media.
83.0% of Vaxxinity shares are owned by institutional investors. Comparatively, 15.9% of Bionomics shares are owned by institutional investors. 64.1% of Vaxxinity shares are owned by company insiders. Comparatively, 1.5% of Bionomics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Vaxxinity has a beta of 2.79, meaning that its stock price is 179% more volatile than the S&P 500. Comparatively, Bionomics has a beta of -0.08, meaning that its stock price is 108% less volatile than the S&P 500.
Bionomics received 11 more outperform votes than Vaxxinity when rated by MarketBeat users. Likewise, 72.73% of users gave Bionomics an outperform vote while only 38.46% of users gave Vaxxinity an outperform vote.
Vaxxinity presently has a consensus price target of $7.00, indicating a potential upside of 12,862.96%. Bionomics has a consensus price target of $9.00, indicating a potential upside of 865.67%. Given Bionomics' higher possible upside, analysts plainly believe Vaxxinity is more favorable than Bionomics.
Vaxxinity's return on equity of 0.00% beat Bionomics' return on equity.
Summary
Bionomics beats Vaxxinity on 8 of the 13 factors compared between the two stocks.
Get Bionomics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BNOX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BNOX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bionomics Competitors List
Related Companies and Tools
